Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2014-11-17
Target enrollment:
Participant gender:
Summary
The purpose of the study is to first determine if temozolomide plus vorinostat in combination
can control relapsed or refractory acute myeloid leukemia (AML) and determine if this
combination can be safely taken. The study will look at the side effects of the Temozolomide
plus Vorinostat in combination and whether the treatment schedule is tolerated.